Stocks TelegraphStocks Telegraph
Stock Ideas

LGND Company Profile and Key Details

NASDAQ : LGND

Ligand Pharmaceuticals

$283.49
-1.21-0.43%
At Close 4:00 PM
73.75
B-ESG ScoreESG Rating

Price Chart

Stock Price Today

Ligand Pharmaceuticals Incorporated (LGND) stock declined over -0.43%, trading at $283.49 on NASDAQ, down from the previous close of $284.70. The stock opened at $285.01, fluctuating between $280.49 and $285.23 in the recent session.

Stock Snapshot

284.7
Prev. Close
5.68B
Market Cap
280.49
Day Low
31.12
P/E Ratio
9.11
EPS (TTM)
-0.24
Cash Flow per Share
285.01
Open
20.04M
Number of Shares
285.23
Day High
97.79%
Free Float in %
40.13
Book Value
372.8K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Sep 18, 2026285.63285.64280.49283.49372.8K
Sep 17, 2026279.51285.51273.10284.70248.81K
Sep 16, 2026277.97278.74271.21275.20299.04K
Sep 15, 2026280.53280.53270.77276.98179.6K
Sep 14, 2026284.93287.14280.12280.65158.77K
Sep 11, 2026291.48294.00283.77284.47261.16K
Sep 10, 2026285.00291.26283.04289.25146.53K
Sep 09, 2026288.03291.82285.48288.05309.96K
Sep 08, 2026285.05289.28278.40288.83216.25K
Sep 04, 2026287.41290.00285.47285.60132.39K
Sep 03, 2026286.92290.08281.88289.74190.29K
Sep 02, 2026285.73290.33281.69286.92189.61K
Sep 01, 2026286.28290.41281.99284.27185.02K
Aug 31, 2026276.77285.90275.60284.10203.67K
Aug 28, 2026283.70284.00277.36280.49127.7K
Aug 27, 2026284.71289.20282.40284.52206.27K
Aug 26, 2026281.72289.66277.01287.85147.46K
Aug 25, 2026284.22287.90278.28281.72197.4K
Aug 24, 2026286.27286.27279.87280.18158.23K
Aug 21, 2026288.09289.98285.21286.29152.54K

Contact Details

Jupiter, FL 33458

United States

https://www.ligand.com858 550 7500

About Company

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Company Information

Employees47
Beta0.98
Sales or Revenue$131.31M
5Y Sales Change%-0.274%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Financial & Profitability Overview

Over the trailing twelve months, Ligand Pharmaceuticals generated $131.31M in revenue, or $7.40 per share. Gross margin was 91.20%, operating margin 7.48%, and net profit margin 39.72%. Returns are modest, with ROA at 6.26% and ROE at 7.44%.
On valuation metrics, Ligand Pharmaceuticals trades at a P/E of 28.32, P/S of 19.55 and P/B of 5.88. The current ratio is 31.18 and quick ratio is 30.96. Operationally, the company’s inventory turnover is 0.40 and cash conversion cycle is 163.84 days. Debt-to-equity is 1.17, supported by a cash flow-to-debt ratio of 0.12.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Ligand Pharmaceuticals posted revenue of $131.31M, down slightly from $196.25M in the prior quarter. Gross profit was $119.75M (margin 91.20%). Operating income was $9.82M (margin 7.5%). Net income was$52.15M (EPS $3.02).
The company ended the quarter with $170.31M in cash and short-term investments, a total debt of $6.17M, and net debt of - $16.79M. Total assets were $833.06M, with equity of $700.91M. Financials further reflected stability, with operating cash flow of $49.58M, free cash flow of - $4.27M, and capital expenditures of - $53.85M.

Frequently Asked Questions

What is the current Ligand Pharmaceuticals Incorporated (LGND) stock price?
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) stock price is $283.49 in the last trading session. During the trading session, LGND stock reached the peak price of $285.23 while $280.49 was the lowest point it dropped to. The percentage change in LGND stock occurred in the recent session was -0.43% while the dollar amount for the price change in LGND stock was - $1.21.
LGND's industry and sector of operation?
The NASDAQ listed LGND is part of Biotechnology industry that operates in the broader Healthcare sector. Ligand Pharmaceuticals Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of LGND?
Ms. Audrey Warfield-Graham
Chief People Officer
Mr. Todd Pettingill
Director of Corporation Devel.
Mr. Matthew E. Korenberg
Pres & Chief Operating Officer
Dr. Vincent D. Antle
Senior Vice President of Technical Operations & QA - Capitsol
Mr. Todd C. Davis
Chief Executive Officer & Director
Mr. John L. Higgins
Executive Director
Simon Latimer
Head of Investor Relations
Dr. Keith Marschke
Senior Vice President of Biology & Scientific Affairs
Mr. Octavio Espinoza
Chief Financial Officer
Mr. Patrick Lucy
Senior Vice President & CBO Protein Expression Bus.
Mr. Andrew T. Reardon J.D.
Chief Legal Officer & Sec.
Mr. Todd C. Davis Ph.D.
Chief Executive Officer & Director
How LGND did perform over past 52-week?
LGND's closing price is 73.44% higher than its 52-week low of $163.45 where as its distance from 52-week high of $326.63 is -13.21%.
How many employees does LGND have?
Number of LGND employees currently stands at 47.
Link for LGND official website?
Official Website of LGND is: https://www.ligand.com
How do I contact LGND?
LGND could be contacted at phone 858 550 7500 and can also be accessed through its website. LGND operates from 555 Heritage Drive, Jupiter, FL 33458, United States.
How many shares of LGND are traded daily?
LGND stock volume for the day was 372.8K shares. The average number of LGND shares traded daily for last 3 months was 351.62K.
What is the market cap of LGND currently?
The market value of LGND currently stands at $5.68B with its latest stock price at $283.49 and 20.04M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph